NCT05142696 2026-03-17
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Novartis
Phase 1/2 Active not recruiting
Clinical Trials
41 trialsNCT05047250 2026-03-11
A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04931342 2026-03-10
BOUQUET
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT05091567 2026-03-10
IMforte
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05361395 2026-03-03
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Amgen
Phase 1 Active not recruiting
NCT06537310 2026-03-03
A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Active not recruiting
NCT04250155 2026-02-24
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Active not recruiting
NCT04660344 2026-02-13
IMvigor011
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04665856 2026-02-13
SKYSCRAPER-02C
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04158258 2026-02-12
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
Hoffmann-La Roche
Active not recruiting
NCT04449874 2026-02-12
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Genentech, Inc.
Phase 1 Active not recruiting
NCT06771622 2026-02-04
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
FBD Biologics Limited
Phase 1/2 Active not recruiting
NCT04661150 2026-01-30
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT04712643 2026-01-30
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05645692 2026-01-30
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT03768063 2026-01-29
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05009069 2026-01-22
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT04543617 2026-01-20
SKYSCRAPER-07
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT03148418 2026-01-13
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03782207 2026-01-08
IMreal
Hoffmann-La Roche
Active not recruiting
NCT05112965 2026-01-07
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03533283 2026-01-06
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT06077500 2026-01-06
DAREONᵀᴹ-8
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT05904886 2025-12-31
SKYSCRAPER-14
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT00781612 2025-12-24
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Genentech, Inc.
Phase 2 Active not recruiting
NCT04446117 2025-12-18
CONTACT-02
Exelixis
Phase 3 Active not recruiting
NCT03755791 2025-12-11
COSMIC-312
Exelixis
Phase 3 Active not recruiting
NCT04185883 2025-10-22
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Phase 1 Active not recruiting
NCT05468489 2025-10-21
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Shanghai Henlius Biotech
Phase 3 Active not recruiting
NCT03520686 2025-10-16
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 3 Active not recruiting
NCT03170960 2025-08-17
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Exelixis
Phase 1 Active not recruiting
NCT05141721 2025-05-16
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Seattle Project Corporation
Phase 2/3 Active not recruiting
NCT06390059 2025-04-30
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
NovoCure Ltd.
Phase 2 Active not recruiting
NCT05243862 2025-03-18
Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
Treos Bio Limited
Phase 2 Active not recruiting
NCT04440735 2025-01-09
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
Kahr Medical
Phase 1/2 Active not recruiting
NCT03845166 2024-11-19
STELLAR-001
Exelixis
Phase 1 Active not recruiting
NCT05022927 2024-09-05
A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma
Chugai Pharmaceutical
Phase 1 Active not recruiting
NCT05878691 2024-07-22
A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.
Glenmark Specialty S.A.
Phase 1 Active not recruiting
NCT05240131 2024-04-12
A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).
Galecto Biotech AB
Phase 1/2 Active not recruiting
NCT04984811 2024-03-05
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
NeoImmuneTech
Phase 2 Active not recruiting